The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression

Laurie E. Littlepage, Adam S. Adler, Hosein Kouros-Mehr, Guiqing Huang, Jonathan Chou, Sheryl R. Krig, Obi L. Griffi th, James E. Korkola, Kun Qu, Devon A. Lawson, Qing Xue, Mark D. Sternlicht, Gerrit J.P. Dijkgraaf, Paul Yaswen, Hope S. Rugo, Colleen A. Sweeney, Colin C. Collins, Joe W. Gray, Howard Y. Chang, Zena Werb

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Fingerprint

Dive into the research topics of 'The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression'. Together they form a unique fingerprint.

Medicine & Life Sciences